CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology ConferenceGlobeNewsWire • 01/11/23
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall StreetThe Motley Fool • 12/31/22
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?Investors Business Daily • 12/22/22
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business DevelopmentGlobeNewsWire • 12/19/22
CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®GlobeNewsWire • 12/12/22
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 12/10/22